Press

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

Oct 6 • 5 min read

Quick Take: The Phase 2 KET-LID clinical trial is a randomized, double-blind, active placebo-controlled study evaluating the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2…

Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD

Oct 5 • 3 min read

Quick Take: Plans to Develop and Launch A Global Registry For The Identification and Long Term Management of Current and Former Boxers With mTBI and PTSD Lobe Sciences Ltd. (CSE: LOBE) is pleased to announce that the Company plans to develop and launch a global registry for the identification and long term management of current…

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Oct 4 • 5 min read

Quick Take: Dr. Inamdar is the recipient of multiple research and development awards for his work in clinical drug development. Cybin Inc. (NYSE:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as…

Mydecine Completes Spin-Out of U.S. Cannabis Assets

Oct 1 • 4 min read

Quick Take: The purpose of the transaction was the comply with U.S. Nasdaq listing requirements as well as London Stock Exchange requirements. Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has completed its previously announced spin-out transaction (the “Transaction”) of ALT…

Braxia Scientific Reports Encouraging Results of Ketamine Study

Sep 30 • 3 min read

Quick Take: The study shows significant reduction in depressive symptoms and suicidality. Braxia Scientific Corp, (CSE: BRAX) (OTC: BRAXF), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441